The changing landscape in translocator protein (TSPO) function

Trends in Endocrinology and Metabolism

Volumn 26, Issue 7, 2015, Pages 341-348

  Selvaraj, Vimal ^a   Stocco, Douglas M ^b  

^a Department of Obstetrics Gynecology   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Benzodiazepine; Cholesterol; Mitochondria; Permeability transition; Steroid hormone; Therapy

Indexed keywords

BIOLOGICAL MARKER; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; OUTER MEMBRANE PROTEIN; TRANSLOCATOR PROTEIN; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; STEROID; TSPO PROTEIN, HUMAN;

AMINO ACID SEQUENCE; BINDING SITE; HUMAN; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; STEROIDOGENESIS; ANIMAL; METABOLISM;

ANIMALS; BIOMARKERS; HUMANS; MITOCHONDRIAL MEMBRANES; RECEPTORS, GABA; STEROIDS;

EID: 84937524245     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2015.02.007     Document Type: Review

References (81)

1. Gavish M., et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol. Rev. 1999, 51:629-650.
2. Rupprecht R., et al. Translocator protein (18kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat. Rev. Drug Discov. 2010, 9:971-988.
3. Scarf A.M., et al. Is there any correlation between binding and functional effects at the translocator protein (TSPO) (18kDa)?. Curr. Mol. Med. 2012, 12:387-397.
4. Fan J., et al. Structural and functional evolution of the translocator protein (18kDa). Curr. Mol. Med. 2012, 12:369-386.
5. Mukhin A.G., et al. Mitochondrial benzodiazepine receptors regulate steroid biosynthesis. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:9813-9816.
6. Papadopoulos V., et al. The peripheral-type benzodiazepine receptor is functionally linked to Leydig cell steroidogenesis. J. Biol. Chem. 1990, 265:3772-3779.
7. Papadopoulos V., et al. Targeted disruption of the peripheral-type benzodiazepine receptor gene inhibits steroidogenesis in the R2C Leydig tumor cell line. J. Biol. Chem. 1997, 272:32129-32135.
8. Hauet T., et al. Peripheral-type benzodiazepine receptor-mediated action of steroidogenic acute regulatory protein on cholesterol entry into Leydig cell mitochondria. Mol. Endocrinol. 2005, 19:540-554.
9. Daugherty D.J., et al. A TSPO ligand is protective in a mouse model of multiple sclerosis. EMBO Mol. Med. 2013, 5:891-903.
10. Lassance L., et al. Obesity-induced downregulation of the mitochondrial translocator protein (TSPO) impairs placental steroid production. J. Clin. Endocrinol. Metab. 2015, 100:E11-E18.
11. Chen C., et al. Estradiol modulates translocator protein (TSPO) and steroid acute regulatory protein (StAR) via protein kinase A (PKA) signaling in hypothalamic astrocytes. Endocrinology 2014, 155:2976-2985.
12. Papadopoulos V., Miller W.L. Role of mitochondria in steroidogenesis. Best Pract. Res. Clin. Endocrinol. Metab. 2012, 26:771-790.
13. Miller W.L. Steroid hormone synthesis in mitochondria. Mol. Cell. Endocrinol. 2013, 379:62-73.
14. McEnery M.W., et al. Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:3170-3174.
15. Zamzami N., Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat. Rev. Mol. Cell Biol. 2001, 2:67-71.
16. Kinnally K.W., et al. Mitochondrial benzodiazepine receptor linked to inner membrane ion channels by nanomolar actions of ligands. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:1374-1378.
17. Chelli B., et al. Peripheral-type benzodiazepine receptor ligands: mitochondrial permeability transition induction in rat cardiac tissue. Biochem. Pharmacol. 2001, 61:695-705.
18. Pastorino J.G., et al. Protoporphyrin IX, an endogenous ligand of the peripheral benzodiazepine receptor, potentiates induction of the mitochondrial permeability transition and the killing of cultured hepatocytes by rotenone. J. Biol. Chem. 1994, 269:31041-31046.
19. Baines C.P., et al. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat. Cell Biol. 2007, 9:550-555.
20. Kokoszka J.E., et al. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 2004, 427:461-465.
21. Giorgio V., et al. Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:5887-5892.
22. Costa B., et al. TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance. Apoptosis 2015, 20:383-398.
23. Azarashvili T., et al. Carbenoxolone induces permeability transition pore opening in rat mitochondria via the translocator protein TSPO and connexin43. Arch. Biochem. Biophys. 2014, 558:87-94.
24. Gemelli C., et al. Cytotoxic effect of hemin in colonic epithelial cell line: involvement of 18kDa translocator protein (TSPO). Life Sci. 2014, 107:14-20.
25. Daniele S., et al. Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma. Sci. Rep. 2014, 4:4749.
26. Bernardi P. The mitochondrial permeability transition pore: a mystery solved?. Front. Physiol. 2013, 4:95.
27. Chen M.K., Guilarte T.R. Translocator protein 18kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol. Ther. 2008, 118:1-17.
28. 11C]PK11195 challengers. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2304-2319.
29. Qi X., et al. Translocator protein (18kDa): a promising therapeutic target and diagnostic tool for cardiovascular diseases. Oxid. Med. Cell. Longev. 2012, 2012:162934.
30. Fairweather D., et al. Sex differences in translocator protein 18kDa (TSPO) in the heart: implications for imaging myocardial inflammation. J. Cardiovasc. Transl. Res. 2014, 7:192-202.
31. Austin C.J., et al. The translocator protein (TSPO): a novel target for cancer chemotherapy. Int. J. Biochem. Cell Biol. 2013, 45:1212-1216.
32. Liu G.J., et al. The 18kDa translocator protein, microglia and neuroinflammation. Brain Pathol. 2014, 24:631-653.
33. Barron A.M., et al. Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease. J. Neurosci. 2013, 33:8891-8897.
34. Rone M.B., et al. Cholesterol transport in steroid biosynthesis: role of protein-protein interactions and implications in disease states. Biochim. Biophys. Acta 2009, 1791:646-658.
35. Rupprecht R., et al. Translocator protein (18kD) as target for anxiolytics without benzodiazepine-like side effects. Science 2009, 325:490-493.
36. Owen D.R., et al. Variation in binding affinity of the novel anxiolytic XBD173 for the 18kDa translocator protein in human brain. Synapse 2011, 65:257-259.
37. Xiao J., et al. 4'-Chlorodiazepam, a translocator protein (18kDa) antagonist, improves cardiac functional recovery during postischemia reperfusion in rats. Exp. Biol. Med. (Maywood) 2010, 235:478-486.
38. Schaller S., et al. TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition. J. Pharmacol. Exp. Ther. 2010, 333:696-706.
39. Morohaku K., et al. Translocator protein/peripheral benzodiazepine receptor is not required for steroid hormone biosynthesis. Endocrinology 2014, 155:89-97.
40. Stocco D.M. The role of PBR/TSPO in steroid biosynthesis challenged. Endocrinology 2014, 155:6-9.
41. Papadopoulos V. On the role of the translocator protein (18-kDa) TSPO in steroid hormone biosynthesis. Endocrinology 2014, 155:15-20.
42. Tu L.N., et al. Peripheral benzodiazepine receptor/translocator protein global knockout mice are viable with no effects on steroid hormone biosynthesis. J. Biol. Chem. 2014, 289:27444-27454.
43. Papadopoulos V., et al. Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Steroids 1997, 62:21-28.
44. Amri H., et al. The peripheral-type benzodiazepine receptor and adrenal steroidogenesis. Curr. Opin. Endocrinol. Diabetes 1999, 6:179-184.
45. Veenman L., et al. Channel-like functions of the 18-kDa translocator protein (TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr. Pharm. Des. 2007, 13:2385-2405.
46. Banati R.B., et al. Positron emission tomography and functional characterization of a complete PBR/TSPO knockout. Nat. Commun. 2014, 5:5452.
47. Tu L.N., et al. PK11195 effect on steroidogenesis is not mediated through the translocator protein (TSPO). Endocrinology 2015, 156:1033-1039.
48. Hatty C.R., et al. Investigating the interactions of the 18kDa translocator protein and its ligand PK11195 in planar lipid bilayers. Biochim. Biophys. Acta 2014, 1838:1019-1030.
49. Paradis S., et al. Cardioprotection by the TSPO ligand 4'-chlorodiazepam is associated with inhibition of mitochondrial accumulation of cholesterol at reperfusion. Cardiovasc. Res. 2013, 98:420-427.
50. Taylor J.M., et al. Targeting mitochondrial 18kDa translocator protein (TSPO) regulates macrophage cholesterol efflux and lipid phenotype. Clin. Sci. (Lond.) 2014, 127:603-613.
51. Chung J.Y., et al. Drug ligand-induced activation of translocator protein (TSPO) stimulates steroid production by aged brown Norway rat Leydig cells. Endocrinology 2013, 154:2156-2165.
52. Sileikyte J., et al. Regulation of the mitochondrial permeability transition pore by the outer membrane does not involve the peripheral benzodiazepine receptor (TSPO). J. Biol. Chem. 2014, 289:13769-13781.
53. Kugler W., et al. Ligands of the mitochondrial 18kDa translocator protein attenuate apoptosis of human glioblastoma cells exposed to erucylphosphohomocholine. Cell. Oncol. 2008, 30:435-450.
54. Sileikyte J., et al. Regulation of the inner membrane mitochondrial permeability transition by the outer membrane translocator protein (peripheral benzodiazepine receptor). J. Biol. Chem. 2011, 286:1046-1053.
55. 0-ATPase. ACS Chem. Biol. 2006, 1:304-308.
56. 0-ATPase by ligands of the peripheral benzodiazepine receptor. Bioorg. Med. Chem. Lett. 2007, 17:1667-1670.
57. 0-ATP synthase in Bcl-2 knock-down cells. Curr. Mol. Med. 2012, 12:476-482.
58. Gut P., et al. Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism. Nat. Chem. Biol. 2013, 9:97-104.
59. Zhou T., et al. The mitochondrial translocator protein, TSPO, inhibits HIV-1 envelope glycoprotein biosynthesis via the endoplasmic reticulum-associated protein degradation pathway. J. Virol. 2014, 88:3474-3484.
60. Gatliff J., et al. TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control. Autophagy 2014, 10:2279-2296.
61. Bae K.R., et al. Translocator protein 18kDa negatively regulates inflammation in microglia. J. Neuroimmune Pharmacol. 2014, 9:424-437.
62. Yeliseev A.A., et al. A mammalian mitochondrial drug receptor functions as a bacterial "oxygen" sensor. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:5101-5106.
63. Vanhee C., et al. The Arabidopsis multistress regulator TSPO is a heme binding membrane protein and a potential scavenger of porphyrins via an autophagy-dependent degradation mechanism. Plant Cell 2011, 23:785-805.
64. Lin R., et al. Genetic analysis of dTSPO, an outer mitochondrial membrane protein, reveals its functions in apoptosis, longevity, and Aβ42-induced neurodegeneration. Aging Cell 2014, 13:507-518.
65. Rampon C., et al. Translocator protein (18kDa) is involved in primitive erythropoiesis in zebrafish. FASEB J. 2009, 23:4181-4192.
66. Arrowsmith J. Trial watch: Phase II failures: 2008-2010. Nat. Rev. Drug Discov. 2011, 10:328-329.
67. Prinz F., et al. Believe it or not: how much can we rely on published data on potential drug targets?. Nat. Rev. Drug Discov. 2011, 10:712.
68. Morohaku K., et al. Developmental expression of translocator protein/peripheral benzodiazepine receptor in reproductive tissues. PLoS ONE 2013, 8:e74509.
69. Midzak A., Papadopoulos V. Binding domain-driven intracellular trafficking of sterols for synthesis of steroid hormones, bile acids and oxysterols. Traffic 2014, 15:895-914.
70. Gonzalez-Polo R.A., et al. PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor. Oncogene 2005, 24:7503-7513.
71. Hans G., et al. Peripheral benzodiazepine receptor (PBR) ligand cytotoxicity unrelated to PBR expression. Biochem. Pharmacol. 2005, 69:819-830.
72. Walter R.B., et al. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood 2005, 106:3584-3593.
73. Li L., et al. The peripheral benzodiazepine receptor ligand 1-(2-chlorophenyl-methylpropyl)-3-isoquinoline-carboxamide is a novel antagonist of human constitutive androstane receptor. Mol. Pharmacol. 2008, 74:443-453.
74. 1-acid glycoprotein: implications for the use of the ligand as a CNS inflammatory marker. Nucl. Med. Biol. 2003, 30:199-206.
75. Stocco D.M. Tracking the role of a star in the sky of the new millennium. Mol. Endocrinol. 2001, 15:1245-1254.
76. 2+-induced membrane transition in mitochondria. I. The protective mechanisms. Arch. Biochem. Biophys. 1979, 195:453-459.
77. 2+ release. Arch. Biochem. Biophys. 1979, 195:468-477.
78. 2+ trigger site. Arch. Biochem. Biophys. 1979, 195:460-467.
79. Papadopoulos V., et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 2006, 27:402-409.
80. Jaremko L., et al. Structure of the mitochondrial translocator protein in complex with a diagnostic ligand. Science 2014, 343:1363-1366.
81. Farges R., et al. Site-directed mutagenesis of the peripheral benzodiazepine receptor: identification of amino acids implicated in the binding site of Ro5-4864. Mol. Pharmacol. 1994, 46:1160-1167.